Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00491049 |
Recruitment Status :
Completed
First Posted : June 25, 2007
Last Update Posted : June 25, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Conjunctival Bacterial Flora | Drug: 0.5% levofloxacin eye drops | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 140 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Prevention |
Official Title: | Phase 4 Study on Effectiveness of Topical 0.5% Levofloxacin on Reduction of Preoperative Conjunctival Flora in Patients Scheduled for Intraocular Surgery |
Study Start Date : | September 2004 |
Actual Study Completion Date : | April 2005 |

- Rate of culture positive results in thioglycolate broth from conjunctival swabs at defined time points [ Time Frame: maximum 7 days before surgery until conclusion of surgery ]
- Numbers of colony forming units (CFUs) found on solid media. Specimens were cultured aerobically and micro-aerobically on blood agar plates and anaerobically on chocolate agar plates and CFUs were determined on each plate using a magnifying glass. [ Time Frame: maximum 7 days before surgery until concluison of surgery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients undergoing surgery for cataract, glaucoma or vitrectomy
Exclusion Criteria:
- Patients who report to be allergic to levofloxacin or iodine
- Patients on topical antibiotic within the last 30 days
- Patients with acute conjunctivitis, blepharitis or dacryocystitis
- Patients under age of 18 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00491049
Germany | |
Augenklinik der LMU | |
Munich, Bavaria, Germany, 80336 |
Principal Investigator: | Herminia Mino de Kapsar, PhD | Augenklinik der LMU |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00491049 |
Other Study ID Numbers: |
LevoProMUC03 |
First Posted: | June 25, 2007 Key Record Dates |
Last Update Posted: | June 25, 2007 |
Last Verified: | June 2007 |
prophylaxis intraocular surgery endophthalmitis antibiotic |
Levofloxacin Ofloxacin Ophthalmic Solutions Pharmaceutical Solutions Anti-Infective Agents, Urinary Anti-Infective Agents Renal Agents Anti-Bacterial Agents |
Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 Enzyme Inhibitors |